1316 related articles for article (PubMed ID: 33879103)
21. Genomic profiling reveals the pivotal role of hrHPV driving copy number and gene expression alterations, including mRNA downregulation of TP53 and RB1 in penile cancer.
Macedo J; Silva E; Nogueira L; Coelho R; da Silva J; Dos Santos A; Teixeira-Júnior AA; Belfort M; Silva G; Khayat A; de Oliveira E; Dos Santos AP; Cavalli LR; Pereira SR
Mol Carcinog; 2020 Jun; 59(6):604-617. PubMed ID: 32212199
[TBL] [Abstract][Full Text] [Related]
22. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations.
Bousquet M; Noirot C; Accadbled F; Sales de Gauzy J; Castex MP; Brousset P; Gomez-Brouchet A
Ann Oncol; 2016 Apr; 27(4):738-44. PubMed ID: 26787232
[TBL] [Abstract][Full Text] [Related]
23. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
Choi W; Ochoa A; McConkey DJ; Aine M; Höglund M; Kim WY; Real FX; Kiltie AE; Milsom I; Dyrskjøt L; Lerner SP
Eur Urol; 2017 Sep; 72(3):354-365. PubMed ID: 28365159
[TBL] [Abstract][Full Text] [Related]
24. Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer.
Zhou H; Hu Y; Luo R; Zhao Y; Pan H; Ji L; Zhou T; Zhang L; Long H; Fu J; Wen Z; Wang S; Wang X; Lin P; Yang H; Wang J; Song M; Yi X; Yang L; Xia X; Guan Y; Fang W; Yang Y; Hong S; Huang Y; Li P; Zhang Y; Zhou N
Nat Commun; 2021 Sep; 12(1):5431. PubMed ID: 34521849
[TBL] [Abstract][Full Text] [Related]
25. TP53 and RB1 alterations characterize poor prognostic subgroups in pediatric acute myeloid leukemia.
Hara Y; Shiba N; Yoshida K; Yamato G; Kaburagi T; Shiraishi Y; Ohki K; Shiozawa Y; Kawamura M; Kawasaki H; Sotomatsu M; Takizawa T; Matsuo H; Shimada A; Kiyokawa N; Tomizawa D; Taga T; Ito E; Horibe K; Miyano S; Adachi S; Taki T; Ogawa S; Hayashi Y
Genes Chromosomes Cancer; 2023 Jul; 62(7):412-422. PubMed ID: 37102302
[TBL] [Abstract][Full Text] [Related]
26. Multi-omics Perspective on the Tumor Microenvironment based on PD-L1 and CD8 T-Cell Infiltration in Urothelial Cancer.
Chen S; Zhang N; Shao J; Wang T; Wang X
J Cancer; 2019; 10(3):697-707. PubMed ID: 30719168
[No Abstract] [Full Text] [Related]
27. Whole-exome mutational landscape of neuroendocrine carcinomas of the gallbladder.
Liu F; Li Y; Ying D; Qiu S; He Y; Li M; Liu Y; Zhang Y; Zhu Q; Hu Y; Liu L; Li G; Pan W; Jin W; Mu J; Cao Y; Liu Y
Signal Transduct Target Ther; 2021 Feb; 6(1):55. PubMed ID: 33563892
[TBL] [Abstract][Full Text] [Related]
28. Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile.
Hoffman-Censits J; Choi W; Pal S; Trabulsi E; Kelly WK; Hahn NM; McConkey D; Comperat E; Matoso A; Cussenot O; Cancel-Tassin G; Fong MHY; Ross J; Madison R; Ali S
Eur Urol Oncol; 2021 Apr; 4(2):297-300. PubMed ID: 32061548
[TBL] [Abstract][Full Text] [Related]
29. Inactivating Mutations of RB1 and TP53 Correlate With Sarcomatous Histomorphology and Metastasis/Recurrence in Gastrointestinal Stromal Tumors.
Merten L; Agaimy A; Moskalev EA; Giedl J; Kayser C; Geddert H; Schaefer IM; Cameron S; Werner M; Ströbel P; Hartmann A; Haller F
Am J Clin Pathol; 2016 Dec; 146(6):718-726. PubMed ID: 28028119
[TBL] [Abstract][Full Text] [Related]
30. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.
Mossanen M; Carvalho FLF; Muralidhar V; Preston MA; Reardon B; Conway JR; Curran C; Freeman D; Sha S; Sonpavde G; Hirsch M; Kibel AS; Van Allen EM; Mouw KW
Eur Urol; 2022 May; 81(5):466-473. PubMed ID: 34953602
[TBL] [Abstract][Full Text] [Related]
31. Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Kim A; Lim SM; Kim JH; Seo JS
Front Immunol; 2021; 12():598671. PubMed ID: 33717076
[TBL] [Abstract][Full Text] [Related]
32. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
33. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
Nyquist MD; Corella A; Coleman I; De Sarkar N; Kaipainen A; Ha G; Gulati R; Ang L; Chatterjee P; Lucas J; Pritchard C; Risbridger G; Isaacs J; Montgomery B; Morrissey C; Corey E; Nelson PS
Cell Rep; 2020 May; 31(8):107669. PubMed ID: 32460015
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics.
Shen P; Jing Y; Zhang R; Cai MC; Ma P; Chen H; Zhuang G
Oncogene; 2018 May; 37(22):3039-3044. PubMed ID: 29535424
[TBL] [Abstract][Full Text] [Related]
35. Next generation sequencing of Cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation.
Harms PW; Collie AM; Hovelson DH; Cani AK; Verhaegen ME; Patel RM; Fullen DR; Omata K; Dlugosz AA; Tomlins SA; Billings SD
Mod Pathol; 2016 Mar; 29(3):240-8. PubMed ID: 26743471
[TBL] [Abstract][Full Text] [Related]
36. A TP53-based immune prognostic model for muscle-invasive bladder cancer.
Li H; Lu H; Cui W; Huang Y; Jin X
Aging (Albany NY); 2020 Dec; 13(2):1929-1946. PubMed ID: 33323544
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas.
Huang RSP; Haberberger J; Harries L; Severson E; Duncan DL; Ferguson NL; Hemmerich A; Edgerly C; Murugesan K; Xiao J; McEwan D; Holmes O; Hiemenz M; Venstrom J; Elvin JA; Creeden J; Lin DI; Ross JS; Ramkissoon SH
Oncologist; 2021 May; 26(5):375-382. PubMed ID: 33687775
[TBL] [Abstract][Full Text] [Related]
38. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
Li L; Li M; Wang X
DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
[TBL] [Abstract][Full Text] [Related]
39. Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer.
Lin A; Qiu Z; Zhang J; Luo P
Front Immunol; 2021; 12():630773. PubMed ID: 33763074
[TBL] [Abstract][Full Text] [Related]
40. Influence of
Naqash AR; Floudas CS; Aber E; Maoz A; Nassar AH; Adib E; Choucair K; Xiu J; Baca Y; Ricciuti B; Alessi JV; Awad MM; Kim C; Judd J; Raez LE; Lopes G; Nieva JJ; Borghaei H; Takebe N; Ma PC; Halmos B; Kwiatkowski DJ; Liu SV; Mamdani H
JCO Precis Oncol; 2024 Feb; 8():e2300371. PubMed ID: 38330261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
